Xillix Technologies Corp. (TSX:XLX), the world leader in fluorescence endoscopy for the early detection of cancer, today announced some of its recent activities in support of November’s Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer death in both men and women with a poor 15% five-year survival rate. The U.S. Food and Drug Administration (FDA) recently approved the Company’s latest device, Onco-LIFETM for use in the detection of lung cancer. FDA approval of Onco-LIFE followed an international multi-center clinical trial which demonstrated that Onco-LIFE improved the detection of subtle early stage lung cancer (carcinoma in situ or Stage 0) and precancerous lesions (moderate-severe dysplasia) by 325% compared to conventional white-light endscopy alone.
